TORONTO, May 22 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. , a developer of real-time imaging and image guidance systems for use in the operating room, today announced that results of a clinical study of the SPY(R) Intra-operative Imaging System in urology was presented at the recent 2008 American Urological Association (AUA) conference in Orlando, Florida. The poster presentation, given by Dragan Golijanin, M.D., a urologist from the University of Rochester, was entitled Near Infrared Fluorescence (NIRF) of Intravenous Indocyanine Green (ICG) for Intra-operative Imaging of Renal Cortical Tumors: A Report on Completed Feasibility Study and was designated as the best poster in its scientific session.
During his moderated poster presentation, Dr. Golijanin reported that in a study of 20 patients, 17 of which underwent partial nephrectomies, all tumor and non-tumorous lesions were clearly delineated by intra-operative SPY imaging. SPY imaging resulted in all malignant lesions being clearly demarcated from normal tissue in the operating room and therefore the ability to perform partial nephrectomy and achieve clean tumor margins was greatly improved. The imaging data was compared with standard pathological outcomes of tissue margin sampling. Dr. Golijanin and his colleagues at the University of Rochester concluded that the use of SPY may allow urologists to diagnose additional lesions, decrease positive surgical margins rate, spare unnecessary resection of normal parenchyma, and preserve renal function.
"Successful partial nephrectomy for the treatment of renal cancer is predicated on the differentiation of lesions, removal of the entire tumor and achievement of negative surgical margins, all while maximizing preservation of normal kidney tissue," said Dr. Golijanin. "Our initial work in partial nephrectomy patients indicates that the use of the SPY System can enable urologists to routinely achieve these goals."
Novadaq's SPY Imaging System is the first and only imaging system that can be used in real-time in the operating room to obtain visual images of blood flow in vessels, perfusion in tissue and organs, and its use in imaging tumors and tumor margins is currently being evaluated. SPY images provide surgeons with information that may contribute to diagnostic and therapeutic procedural decisions that may optimize a variety of surgical operations for individual patients.
About Novadaq Technologies
Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT(TM), its first minimally invasive imaging system for autofluorescence in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO(2) HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX(R) System, which leverages the company's core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at www.novadaq.com.
Forward looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: visit our website at www.novadaq.com, or contact: Arun Menawat,
PhD, MBA, President & CEO, Novadaq Technologies Inc., (905) 629-3822 x 202,
amenawat@novadaq.com; Michael Moore, Investor Relations, The Equicom Group,
(416) 815-0700 x 241, mmoore@equicomgroup.com
